Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development ...
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an ...
To get a sense of who is truly in control of Cartesian Therapeutics, Inc. (NASDAQ:RNAC), it is important to understand the ownership structure of the business. We can see that individual insiders own ...
Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback